This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Tumour Impact

The majority of pituitary tumours remain stable with Somavert1

  • Although Somavert does not directly act on the pituitary tumour, 96.3% of patients experience maintained or decreased tumour size while on Somavert*1
  • Treatment-resistant tumour progression occurs in a small minority of patients with acromegaly, regardless of treatment modality2
  • When no tumour growth is observed in the first 18 months of treatment with Somavert, it is unlikely that any growth will occur subsequently3​​​​​​​

*As assessed by local ± central MRI analysis.​​​​​​​

Tumour stability during ACROSTUDY1,4

​​​​​​​

Treatment impact on the tumour

Professor Richard Ross, Consultant Endocrinologist, University of Sheffield, discusses the various treatments for acromegaly and how they each impact the pituitary tumour

Track IGF-I, symptoms and co-morbidities with ACRODAT

Learn more

Explore more

Contact us 

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

Treatment impact on diabetes 

Professor Partha Kar, Consultant in Diabetes and Endocrinology, Portsmouth Hospital NHS Trust, discusses the impact of acromegaly and its treatments on glycaemic control and diabetes

Explore more webinars

References 

1. ACROSTUDY data on file. Final study report. November 2018.
2. Besser GM et al. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005;153:187–93.
3. Jiminez et al., Follow-up of pituitary tumour volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008: 159(5): 517–23.
4. Buchfelder M, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol, 2018;179(6):419–27.

PP-SOM-GBR-0952. June 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No